Dataset opportunity
Promocell — Downloadable Data Asset Opportunity
Large downloadable data asset held by Promocell, usable for Fine Tuning and Pretraining.
Score
70.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
64%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global cell culture market was valued at $19.39 billion in 2025, projected to grow at a 13.14% CAGR.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Downloadable Data Asset
Modality
Tabular
Sector
healthcare
Volume
Large
Freshness
Periodic
Rarity
Medium
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Domain LLM builders & vertical AI startups
PromoCell's downloadable asset is a Tabular dataset providing an integrated view of human primary cells, including medical_records, industrial_data like lot-specific biological sample behavior, and regulatory details. This rich, structured data, which links donor metadata to proprietary cell culture formulations and outcomes, is exceptionally well-suited for the Fine Tuning of complex AI models aimed at predictive biology and accelerating drug discovery.
This data is a critical asset in the global cell culture market, a sector valued at $19.39 billion in 2025 and projected to grow at a 13.14% CAGR. While access is subject to GDPR and trade secret negotiations, the rarity of data that is deeply linked to physical samples makes it highly valuable. It offers a distinct competitive advantage for AI-driven pharmaceutical companies looking to innovate within this high-growth market. ⚠ Diligence (valuable data, access to negotiate): Human donor metadata is subject to strict GDPR and ethical constraints; Data is deeply linked to physical biological samples and lot numbers; Proprietary cell culture formulations are likely protected as trade secrets · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Promocell holds a valuable, multi-modal dataset covering the cell culture lifecycle, from granular donor medical records to real-time industrial process monitoring and GMP-grade regulatory documentation. This asset is a powerful resource for domain LLM builders and vertical AI startups seeking to fine-tune models for the rapidly growing $19 billion global cell culture market. Acquiring this data provides a direct path to developing specialized AI for biomanufacturing optimization, predictive biology, and automated regulatory compliance, creating a significant competitive moat.
See dimension details ↓- Dataset Specificity90
dominant 'downloads', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity58
proprietary domain data (open lowers rarity)
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume82
8 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/open (current)
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Fine Tuning
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
AI buyer demand is driven by the rapid 13.14% CAGR of the cell culture market, creating a strong need for high-quality, proprietary data to fine-tune predictive models for biopharmaceutical R&D.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
open/API access
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength86
4 evidence types, 8 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit92
✓ good target — PromoCell is a strong target as it manufactures and sells physical cell culture products, generating a vast amount of valuable, niche R&D and QC data as a by-product which it does not appear to be monetizing as a core business. Issues: The company has been named one of the most attractive medium-sized companies to work for in Germany, suggesting it may be on the larger side of SME, but likely ; The data is derived from human tissue donors, which carries strict privacy and ethical obligations (e.g., GDPR), and the company is very aware of this.; The company offers an 'Extended Right of Use' for commercial applications of its cells, which is a service but not a raw data product.
- Deep Qualification90
✓ pass — PromoCell is a strong data_holder candidate. It sells human cells and culture media, generating a valuable byproduct dataset of donor metadata (including HLA-typing), cell behavior, and formulation performance, which is highly relevant for AI in drug discovery. However, the data is subject to strict GDPR and ethical constraints, and its commercial reuse requires negotiating a specific 'Extended Right of Use' license.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Downloads / exports
The evidence points to downloadable application notes, providing structured tabular data on technical protocols valuable for training models on established cell culture procedures.
Medical records / imaging
The asset contains detailed medical records, including specific donor information like age, sex, and HLA-type, which is critical for developing AI that predicts outcomes based on patient demographics.
Industrial data
The holder generates time-series industrial data from the automated, real-time analysis of cell proliferation and metabolic activity, a key input for AI models aimed at optimizing biomanufacturing processes.
Regulatory records
The dataset includes text-based regulatory information reflecting decades of expertise and adherence to GMP-grade standards, essential for fine-tuning language models on the nuances of biopharma compliance.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Promocell Downloadable Data — a Large downloadable data asset (Tabular modality) in the healthcare domain. Primary AI use-case: Fine Tuning. Market signal: Global cell culture market was valued at $19.39 billion in 2025, projected to grow at a 13.14% CAGR (source: Fortune Business Insights).. Investment score 70.8/100 (confidence 0.64). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Alaiko — Tabular Data Export Opportunity
View opportunity →healthcareHistosonics — Medical Imaging Dataset Opportunity
View opportunity →healthcareQuantadt — Medical Imaging Dataset Opportunity
View opportunity →